SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia

Area of Science:

• Molecular Biology
• Oncology
• Hematology

Background:

• Alterations in RNA splicing are linked to cancer development and progression.
• Chronic lymphocytic leukemia (CLL) exhibits heterogeneous outcomes, with spliceosome gene mutations and alternative splicing observed.
• SET oncoprotein levels correlate with CLL aggressiveness, but the role of alternative splicing in regulating kinases and phosphatases in CLL is unclear.

Purpose of the Study:

• To investigate the impact of alternative splicing of gene transcripts regulating kinases and phosphatases on CLL pathobiology and progression.
• To determine if alternative splicing of SET isoforms affects disease severity and patient outcomes in CLL.

Main Methods:

• Analysis of mRNA levels of alternatively spliced SET isoforms (SETA and SETB) in CLL patients.
• Correlation of SET isoform mRNA levels with clinical parameters such as overall survival and time-to-first-treatment.
• Validation of findings using an independent CLL cohort.

Main Results:

• mRNA levels of SETA and SETB isoforms significantly correlate with CLL disease severity, including overall survival and time-to-first-treatment.
• A higher ratio of SETA to SETB mRNA can distinguish patients with more aggressive disease within favorable CLL risk groups.
• Findings were validated in an independent CLL cohort, confirming the relationship between SET mRNA levels and disease outcomes.

Conclusions:

• Alternative splicing of the SET gene influences CLL biology and patient outcomes.
• SETA/SETB mRNA ratio serves as a potential biomarker for predicting aggressive disease course in CLL.
• Alternative splicing of signaling cascade molecules may play a broader role in CLL progression.